A Bayesian time-to-event pharmacokinetic model for phase I dose-escalation trials with multiple schedules
From MaRDI portal
Publication:6629855
DOI10.1002/sim.8703zbMATH Open1546.62284MaRDI QIDQ6629855
Tim Friede, Burak Kürsad Günhan, Sebastian Weber
Publication date: 30 October 2024
Published in: Statistics in Medicine (Search for Journal in Brave)
Cites Work
- Unnamed Item
- Unnamed Item
- Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
- Inference from iterative simulation using multiple sequences
- A Phase I Bayesian Adaptive Design to Simultaneously Optimize Dose and Schedule Assignments Both Between and Within Patients
- Using Joint Utilities of the Times to Response and Toxicity to Adaptively Optimize Schedule–Dose Regimes
- Robust meta‐analytic‐predictive priors in clinical trials with historical control information
- Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities
- Handbook of Methods for Designing, Monitoring, and Analyzing Dose-Finding Trials
- Dose‐finding methods for Phase I clinical trials using pharmacokinetics in small populations
- A dose-schedule finding design for phase I-II clinical trials
Related Items (4)
Bayesian modeling of a bivariate toxicity outcome for early phase oncology trials evaluating dose regimens ⋮ Extending the continual reassessment method to accommodate step-up dosing in phase I trials ⋮ Practical implementation of the partial ordering continual reassessment method in a phase I combination-schedule dose-finding trial ⋮ An extended Bayesian semi-mechanistic dose-finding design for phase I oncology trials using pharmacokinetic and pharmacodynamic information
This page was built for publication: A Bayesian time-to-event pharmacokinetic model for phase I dose-escalation trials with multiple schedules
